Division of Rheumatology, University Hospitals of Geneva, 26 Avenue de Beau-Séjour, 1211 Geneva 14, Switzerland.
Nat Rev Rheumatol. 2014 Nov;10(11):639-40. doi: 10.1038/nrrheum.2014.156. Epub 2014 Sep 9.
Given the known involvement of IL-36 in psoriasis it might be surprising that the latest mouse models show that inhibiting IL-36 signalling does not alter the course of inflammatory arthritis. Can we now add IL-36 to the list of inflammatory mediators that are not viable DMARD targets?
鉴于白细胞介素-36（IL-36）已知与银屑病有关，最新的小鼠模型表明抑制 IL-36 信号传导并不会改变炎症性关节炎的病程，这可能令人惊讶。我们现在可以将白细胞介素-36（IL-36）添加到那些不是可行的疾病修饰抗风湿药物（DMARD）靶点的炎症介质列表中吗？
